Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

Rogelio Apiquian1, Rodrigo C&oacute;rdoba2, Mario Louz&atilde;31Americas University, Behavior and Development Sciences Division, Mexico City, Mexico; 2Nervous System Research Center-CISNE, Bogota, Colombia; 3Schizophrenia Research Program, Institute of Psychiatry, Faculty of Medicine...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mario Louz&atilde;, Rodrigo C&oacute;rdoba, Rogelio Apiquian
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a4cf1195b9a540ce9ab540479d3bb2f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a4cf1195b9a540ce9ab540479d3bb2f1
record_format	dspace
spelling	oai:doaj.org-article:a4cf1195b9a540ce9ab540479d3bb2f12021-12-02T02:58:42ZClinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America1176-63281178-2021https://doaj.org/article/a4cf1195b9a540ce9ab540479d3bb2f12010-12-01T00:00:00Zhttp://www.dovepress.com/clinical-outcomes-of-long-acting-injectable-risperidone-in-patients-wi-a5955https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Rogelio Apiquian1, Rodrigo C&oacute;rdoba2, Mario Louz&atilde;31Americas University, Behavior and Development Sciences Division, Mexico City, Mexico; 2Nervous System Research Center-CISNE, Bogota, Colombia; 3Schizophrenia Research Program, Institute of Psychiatry, Faculty of Medicine, University of S&atilde;o Paulo, BrazilBackground: Risperidone long-acting injection (RLAI) has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America.Methods: Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S), Personal and Social Performance (PSP), and Global Assessment of Functioning (GAF) scores. Relapse and treatment were also registered.Results: Patients were recruited in Mexico (n = 53), Brazil (n = 11), and Colombia (n = 15). Sixty-five percent (n = 52) were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73) or schizoaffective disorder (n = 6). The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg). The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P &lt; 0.001). Significant changes were registered on CGI-S, GAF, and PSP scores.Conclusions: RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization.Keywords: long-acting, risperidone, schizophrenia, schizoaffective disorder, Latin America Mario Louz&atilde;Rodrigo C&oacute;rdobaRogelio ApiquianDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss default, Pp 19-26 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Mario Louz&atilde; Rodrigo C&oacute;rdoba Rogelio Apiquian Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
description	Rogelio Apiquian1, Rodrigo C&oacute;rdoba2, Mario Louz&atilde;31Americas University, Behavior and Development Sciences Division, Mexico City, Mexico; 2Nervous System Research Center-CISNE, Bogota, Colombia; 3Schizophrenia Research Program, Institute of Psychiatry, Faculty of Medicine, University of S&atilde;o Paulo, BrazilBackground: Risperidone long-acting injection (RLAI) has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America.Methods: Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S), Personal and Social Performance (PSP), and Global Assessment of Functioning (GAF) scores. Relapse and treatment were also registered.Results: Patients were recruited in Mexico (n = 53), Brazil (n = 11), and Colombia (n = 15). Sixty-five percent (n = 52) were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73) or schizoaffective disorder (n = 6). The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg). The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P &lt; 0.001). Significant changes were registered on CGI-S, GAF, and PSP scores.Conclusions: RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization.Keywords: long-acting, risperidone, schizophrenia, schizoaffective disorder, Latin America
format	article
author	Mario Louz&atilde; Rodrigo C&oacute;rdoba Rogelio Apiquian
author_facet	Mario Louz&atilde; Rodrigo C&oacute;rdoba Rogelio Apiquian
author_sort	Mario Louz&atilde;
title	Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
title_short	Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
title_full	Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
title_fullStr	Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
title_full_unstemmed	Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
title_sort	clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the electronic schizophrenia treatment adherence registry in latin america
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/a4cf1195b9a540ce9ab540479d3bb2f1
work_keys_str_mv	AT mariolouzampatilde clinicaloutcomesoflongactinginjectablerisperidoneinpatientswithschizophreniasixmonthfollowupfromtheelectronicschizophreniatreatmentadherenceregistryinlatinamerica AT rodrigocampoacuterdoba clinicaloutcomesoflongactinginjectablerisperidoneinpatientswithschizophreniasixmonthfollowupfromtheelectronicschizophreniatreatmentadherenceregistryinlatinamerica AT rogelioapiquian clinicaloutcomesoflongactinginjectablerisperidoneinpatientswithschizophreniasixmonthfollowupfromtheelectronicschizophreniatreatmentadherenceregistryinlatinamerica
_version_	1718402061108772864

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

Ejemplares similares